Morphocell raises $50m to boost liver tissue therapies

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Morphocell’s expanded Series A funding strengthens its plans to advance engineered liver tissue therapies and scale globally.

Morphocell Technologies Inc, a Canadian biotech working to create next-generation tissue therapeutics for organ replacement, has closed its Series A financing at US$50 million, following a new US$10 million extension led by Investissement Québec and CDP Venture Capital [1].

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Kyle Umipig

Kyle has nine years of editorial writing experience. They have been following the longevity sector since 2022, focusing on research, emerging tech, and the companies shaping the future of aging and age-related health.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Beauty giant and supplement startup both chase skin aging

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE